Tong Ren Tang Technologies CoTGRNF 50 Net Current Asset Value is $0.42 as of Dec. 2025, which is 85% below its 10-year median of 2.85. GuruFocus rates TGRNF with a GF Score™ of 50/100 and a GF Value™ of $0.84 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 613 Drug Manufacturers companies, Tong Ren Tang Technologies Co ranks better than 93.8% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Tong Ren Tang Technologies Co's net current asset value per share for the quarter that ended in Dec. 2025 was $0.42.
The historical rank and industry rank for Tong Ren Tang Technologies Co's Net Current Asset Value or its related term are showing as below:
TGRNF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.95 Med: 2.85 Max: 6.09
Current: 0.95
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Tong Ren Tang Technologies Co was 6.09. The lowest was 0.95. And the median was 2.85.
TGRNF's Price-to-Net-Current-Asset-Value is ranked better than 93.8% of 613
companies
in the Drug Manufacturers industry
Industry Median: 5.63
vs TGRNF: 0.95
Tong Ren Tang Technologies Co (OTCPK:TGRNF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Tong Ren Tang Technologies Co Net Current Asset Value Related Terms
Tong Ren Tang Technologies Co Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tong Ren Tang Technologies Co Net Current Asset Value Chart
TGRNF vs LLY, JNJ, ABBV: Net Current Asset Value Comparison
For the Drug Manufacturers - General subindustry, Tong Ren Tang Technologies Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tong Ren Tang Technologies Co Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tong Ren Tang Technologies Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Tong Ren Tang Technologies Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.42 mean?
Tong Ren Tang Technologies Co (TGRNF) has a Net Current Asset Value of $0.42 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Tong Ren Tang Technologies Co and its competitors. This is 85% below median its historical median of 2.85. Over the past decade, Tong Ren Tang Technologies Co's Net Current Asset Value has ranged from 0.95 to 6.09. According to the industry distribution chart, Tong Ren Tang Technologies Co ranks #38 out of 613 companies in the Drug Manufacturers industry, placing it in the top 6.2%.
Is Tong Ren Tang Technologies Co's Net Current Asset Value too high?
Tong Ren Tang Technologies Co's current Net Current Asset Value of $0.42 is 85% below median its 10-year median of 2.85. Over the past 10 years, this metric has ranged from a low of 0.95 to a high of 6.09. The Drug Manufacturers industry median Net Current Asset Value is 5.63. Tong Ren Tang Technologies Co's value of $0.42 is 92.5% below this industry median. Based on the distribution chart, Tong Ren Tang Technologies Co ranks #38 out of 613 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tong Ren Tang Technologies Co has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tong Ren Tang Technologies Co's Net Current Asset Value compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Tong Ren Tang Technologies Co ranks #38 out of 613 companies for Net Current Asset Value. This places Tong Ren Tang Technologies Co in the top 6% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 5.63. Tong Ren Tang Technologies Co's value of $0.42 is 92.5% below this benchmark. Historically, Tong Ren Tang Technologies Co's own Net Current Asset Value has ranged from 0.95 to 6.09 over the past decade. While the company's 10-year median is 2.85 vs. the industry median of 5.63, Tong Ren Tang Technologies Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.63, based on 613 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tong Ren Tang Technologies Co's current Net Current Asset Value of $0.42 is 92.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Tong Ren Tang Technologies Co and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tong Ren Tang Technologies Co's current Net Current Asset Value is $0.42, which is 85% below median its own 10-year median of 2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tong Ren Tang Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Tong Ren Tang Technologies Co (TGRNF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.84, compared to a current price of $0.49 — trading 41.1% below its estimated fair value. The current Net Current Asset Value is $0.42, which is 85% below median its 10-year median of 2.85 and 92.5% below the Drug Manufacturers industry median of 5.63. Tong Ren Tang Technologies Co's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Tong Ren Tang Technologies Co (TGRNF), the current Net Current Asset Value is $0.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tong Ren Tang Technologies Co (TGRNF) Overvalued in 2026?
Based on GuruFocus' analysis, Tong Ren Tang Technologies Co stock appears to be undervalued.
The current stock price of $0.49 is trading 41.1% below its estimated GF Value™ of $0.84.
GuruFocus considers Tong Ren Tang Technologies Co to be Significantly Undervalued.
Key valuation signals for TGRNF:
Net Current Asset Value: $0.42 (85% below median its 10-year median of 2.85)
GF Value™: $0.84 vs. price of $0.49 (41.1% below fair value)
Industry Position: 92.5% below the Drug Manufacturers median (#38 of 613)
No single metric tells the full story. See the TGRNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tong Ren Tang Technologies Co Business Description
Tong Ren Tang Technologies Co Ltd is engaged in the production and distribution of Chinese medicine and predominantly operates in Mainland China and Hong Kong. The operating segments derive their revenue predominantly from the manufacture and sale of Chinese medicine of the company in Mainland China and Tong Ren Tang Chinese Medicine and its subsidiaries engaged in manufacturing, retail, and wholesale of Chinese medicine products and healthcare products, and provision of Chinese medical consultation and treatments outside Mainland China and wholesale of healthcare products in Mainland China.
50GF Score
Get the complete analysis for TGRNF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TGRNF has been successfully added to your 
